Clinical trial
An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
NCT03391765 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)
- Lead sponsor
- AbbVie
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 24, 2018
- Completion date
- December 13, 2019
- Enrollment
- 142 (actual)
- Sites
- 42
Conditions
As the registry lists them; a condition with its own page is linked.
progressive supranuclear palsy (psp)